BTK-IN-19

Modify Date: 2023-04-18 20:19:10

BTK-IN-19 structure	Common Name	BTK-IN-19
	CAS Number	1374240-01-3	Molecular Weight	445.34
	Density	N/A	Boiling Point	N/A
	Molecular Formula	C₂₁H₂₂Cl₂N₆O	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of BTK-IN-19

BTK-IN-19 (Compound 51) is a reversible BTK inhibitor with an IC50 of <0.001 μM[1].

Name	BTK-IN-19

Description	BTK-IN-19 (Compound 51) is a reversible BTK inhibitor with an IC50 of <0.001 μM[1].
Related Catalog	Research Areas >> Inflammation/Immunology Signaling Pathways >> Protein Tyrosine Kinase/RTK >> Btk
Target	IC50: <0.001 μM (BTK)[1]
In Vitro	BTK-IN-19 (Compound 51) (3 days) inhibits B-cell proliferation with an IC50 of 0.080 μM[1].BTK-IN-19 (Compound 51) (3 days) 抑制 B 细胞增殖，IC50 为 0.080 μM[1]。 Cell Proliferation Assay[1] Cell Line: B cells enriched from PBMC Concentration: Incubation Time: 3 days Result: Inhibited B-cell proliferation with an IC50 of 0.080 μM.
In Vivo	BTK-IN-19 (Compound 51) (80 mg/kg; i.p.; once) 在小鼠中抑制 CD69[1]。 BTK-IN-19 (5 mg/kg; p.o.) 在大鼠中体内清除率低，具有适中的口服利用度 (%F > 34) [1]。 Animal Model: DBA/1 mice[1] Dosage: 80 mg/kg Administration: IP, once Result: Demonstrated strong inhibition of CD69.
References	[1]. Vandeveer GH, et al. Discovery of structural diverse reversible BTK inhibitors utilized to develop a novel in vivo CD69 and CD86 PK/PD mouse model. Bioorg Med Chem Lett. 2022 Dec 17;80:129108.

Molecular Formula	C₂₁H₂₂Cl₂N₆O
Molecular Weight	445.34